$4568 (+2,36 %) The stock has fallen significantly today, at times reaching as low as -10%. Yet there is positive news: Enhertu has now been officially approved in the EU and China as a treatment for breast cancer. I couldn’t find any explanation for why the stock is falling despite this. I don’t really care, though—my investment thesis remains intact, and I’m still targeting 2030 and Datroway. But I’m happy to take news like this in stride. My break-even point has been reached again; if the price drops further, I’ll consider buying more here.

Current price: €14.78

https://www.finanzen.at/nachrichten/aktien/astrazeneca-aktie-eu-kommission-gibt-brustkrebsmedikament-frei-1036669910

$4568 (+2,36 %) falls below the next threshold and the next KO is placed at €13.

and thanks to customer service for not being able to make the content of the post disappear.

Now we have to wait and see what the postponement of the quarterly figures means. The buy order was triggered automatically and was actually set at €14.50. Then you wake up and get the news. Let's see what happens.

After I had missed to add some 2 weeks ago, I immediately placed a buy order and this was triggered today. More Daiichi, more Datroway. The reorganization of the Group with the sale of the healthcare division and increased focus on research is just what I need.

After stumbling across the drug Datroway in an internal presentation, I took a closer look at the manufacturer. The result was a profitable BioTech company with a great pipeline, which is already profitable and growing strongly. As a small pearl, there is a small dividend on top.

Mr. Prompt and the dear @Raketentoni confirmed my assessment once again, so I couldn't keep my hands off it today and added it to my portfolio as a satellite.

I was still considering whether it would be the $DSNKY ADR or the original, but GPT convinced me of the original.

What do you think of $4568 (+2,36 %) ?

$4568 (+2,36 %) together with $AZN (+6,73 %) is currently developing the drug Datroway (breast cancer). Sales revenues of around € 6 billion are expected by 2030:

https://www.fiercepharma.com/marketing/top-10-most-anticipated-drug-launches-2025#:~:text=It's%20already%20off%20to%20a,out%20last%20year's%20roundup%20here.

What do you think of the share? There is still a dividend and the share price has been down 30% for a year. Irritates me a little. Any opinions?

Hello everyone,

Are there any $4568 (+2,36 %) Daiichi Sankyo with Trade Republic? I was thinking about possibly adding a savings plan here and have just realized that this doesn't seem to be possible.

Is this normal or is it the same for some people? Or are there possibly other reasons for this?

Many thanks in advance for your knowledge.